<DOC>
	<DOCNO>NCT02728843</DOCNO>
	<brief_summary>The goal study evaluate effect deferiprone , iron-chelating drug , patient Parkinson 's disease . Participants randomize receive one four different dosage deferiprone placebo , take assign study product twice day nine month .</brief_summary>
	<brief_title>Study Parkinson 's Early Stage With Deferiprone</brief_title>
	<detailed_description>This study enroll 140 patient diagnose Parkinson 's disease within last 3 year currently take antiparkinsonian medication . There four dosage cohort , patient cohort receive either deferiprone tablet placebo . At baseline visit , participant randomize dosage cohort either active product placebo within cohort , take assign study product twice-daily 9 month . They come back study site assessment Months 1 , 2 , 3 , 4 , 5 , 6 , 9 , need blood count check weekly , either study site local laboratory .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Deferiprone</mesh_term>
	<criteria>Male female age ≥18 &lt; 80 year Body weight ≥60 kg ≤100 kg Parkinson 's disease diagnose Absolute neutrophil count ( ANC ) ≥1.5 x 10^9/L ( ≥1.0 x 10^9/L Black population ) screen On stable dose least 3 month prior screen visit follow treatment Ldopa equivalent daily dose 600 mg : Dopaminergic agonist alone Ldopa alone Combination therapy dopaminergic agonist Ldopa Rasagiline At early stage disease , without motor fluctuation and/or Ldopainduced dyskinesia Diagnosis Parkinson 's disease 3 year prior screen visit Hoehn Yahr stage ≥ 3 Atypical secondary Parkinsonism without dopasensitivity ( e.g. , vascular parkinsonism , supranuclear palsy , multisystem atrophy ) Progressing Axis I psychiatric disorder ( psychosis , hallucination , compulsive disorder , substance addiction , bipolar disorder , severe depression , anxiety ) assess semistructured interview accordance Diagnostic Statistical Manual Mental Disorders Not stabilize term current antiparkinsonian therapeutic regimen : already require dose adaptation and/or likely require change dopamine therapy duration trial Current treatment bromocriptine Current treatment antiparkinsonian drug list inclusion criterion Current treatment coenzyme Q10 idebenone . ( Patients medication stop take least 2 week prior baseline may enrol . ) Current use Deep Brain Stimulation ( DBS ) system . ( Patients previously DBS system remove may enrol . )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Parkinson 's disease</keyword>
	<keyword>Deferiprone</keyword>
</DOC>